论文部分内容阅读
目的观察参芪注射液对蒽环类治疗后的转移性乳腺癌联合治疗中的作用。方法 58例经蒽环类治疗后复发转移的乳腺癌患者采用紫杉醇联合卡培他滨治疗,将58例患者分为2组,对照组28例采用紫杉醇270mg静脉滴注第1天,卡培他滨2000 mg/m~2口服,2次/d,连服2周,休息l周,3周为一疗程;治疗组30例在联合治疗的同时静脉滴注参芪注射液250 mL,1次/d,连用10 d,每个周期观察疗效和记录不良反应。结果治疗组总有效率33.3%,病情稳定率83.3%;对照组总有效率32.1%,病情稳定率67.9%。治疗后2组的外周血T细胞亚群有不同程度改变;治疗组优于对照组(P<0.05);不良反应有骨髓抑制、消化道反应、手足综合征、乏力以及心电图改变等,治疗组不良反应发生率明显低于对照组(P<0.05)。结论参芪注射液在紫杉醇联合卡培他滨治疗转移性乳腺癌中,能明显提高疗效,降低不良反应,改善患者生活质量,提高机体免疫力。
Objective To observe the effect of Shenqi Injection on the combined treatment of metastatic breast cancer after anthracycline treatment. Methods Fifty-eight patients with recurrence and metastasis of breast cancer after treatment with anthracycline were treated with paclitaxel and capecitabine. 58 patients were divided into two groups. In the control group, 28 patients received intravenous infusion of paclitaxel 270mg on the first day and capecitabine The patients in the treatment group were treated with intravenous infusion of Shenqi injection 250 mL once a day for 2 weeks at a dose of 2000 mg / / d, once every 10 d, observe the efficacy of each cycle and record adverse reactions. Results The total effective rate was 33.3% in the treatment group and the disease stability was 83.3%. The total effective rate in the control group was 32.1% and the stable rate was 67.9%. After treatment, T lymphocyte subsets in peripheral blood of the two groups changed to some extent; the treatment group was better than the control group (P <0.05); the adverse reactions were bone marrow suppression, digestive tract reaction, hand-foot syndrome, fatigue and electrocardiogram changes. The incidence of adverse reactions was significantly lower than that of the control group (P <0.05). Conclusion Shenqi injection in paclitaxel combined with capecitabine in the treatment of metastatic breast cancer, can significantly improve the efficacy, reduce adverse reactions, improve patient quality of life and improve immunity.